Should We Completely Exclude Locoregional Therapy for the Primary Tumor from Our Clinical Practice in De Novo Metastatic Breast Cancer?

Abstract

Locoregional therapy (LRT) for the primary site of breast cancer (BC) is one of the most debated topics in de novo metastatic disease. We have four main randomized controlled trials, three negative and one positive, together with one positive prospectively designed non-randomized study investigating the contribution of LRT to the literature. We aimed to discuss the possible reasons for the positive or negative results of the studies and to identify specific subgroups that may benefit from primary breast surgery.

Keywords: Breast cancer; Locoregional therapy; Metastatic disease; Surgery.